Search

Your search keyword '"Blasi, L"' showing total 306 results

Search Constraints

Start Over You searched for: Author "Blasi, L" Remove constraint Author: "Blasi, L"
306 results on '"Blasi, L"'

Search Results

4. Oxycodone/Acetaminophen: The Tailoring Combination Treatment for Specific Clinical Profile of Opioid Well-Responsive Cancer Pain

6. Clinical efficacy of nab-paclitaxel in patients with metastatic pancreatic cancer

7. Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA study

12. Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial

13. Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies

14. Nutritional management of the patient with pancreatic cancer: from the diagnostic and therapeutic pathway to an integrated hospital-territory approach.

15. PD-0672 Cardiac toxicity predicts mortality in NSCLC patients: interim analysis of the LUNG-HEART Study

17. OC-0925 Early adjuvant RT as a predictor of improved outcomes in patients with grade II and III meningiomas

18. THE KEY ROLE OF THE CLINICAL PHARMACIST IN THE MANAGEMENT OF ANTICANCER THERAPIES: A PILOT STUDY IN THE TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CANCER

21. Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA study

22. Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to success

23. Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to success

25. ACCORDION D3.1 - Edge infrastructure pool framework report (I)

26. Efficacy and Safety of Pertuzumab in Metastatic Breast Cancer Patients in a Real-World Setting: Results from the SUPER-GONO (Gruppo Oncologico Del Nord Ovest) Study

27. Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial (Journal of Translational Medicine, (2020), 18, 1, (405), 10.1186/s12967-020-02573-9)

29. Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study

30. Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study

31. Correction: Everolimus (Eve) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study (Oncotarget (2018) 9:77 (34639-34640) DOI: 10.18632/oncotarget.25874)

32. Erratum: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study (Oncotarget (2018) 9 (31877-31887) DOI: 10.18632/oncotarget.25874)

33. ACCORDION - D2.2 State of the art report (I)

34. ACCORDION D7.5 - Technoeconomic analysis (I)

35. ACCORDION D2.3 - Architecture design (I)

37. 290P From the CLEOPATRA study to real life: Final results from the G.O.N.O. SUPER trial

38. 1705P SARS-CoV-2 infection among cancer patients receiving antitumor treatment in Italy: A nationwide observational study (CIPOMO ONCO COVID-19)

40. Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA study

49. Whatsapp messenger as a tool for the multidisciplinary management in everyday clinical practice

Catalog

Books, media, physical & digital resources